drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00526 | DB01250 | 1,555 | 712 | [
"DDInter1355",
"DDInter1334"
] | Oxaliplatin | Olsalazine | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Olsalazine is an aminosalicylate and a prodrug of [mesalamine] (5-aminosalicylic acid, 5-ASA). It was first developed for delivering mesalamine to the colon without the use of [sulfapyridine]. Olsalazine comprises two mesalamine molecules joined by an azo bridge, which is cleaved in the colon. Olsalazine is an anti-inf... | Moderate | 1 | [
[
[
1555,
24,
712
]
],
[
[
1555,
24,
50
],
[
50,
40,
712
]
],
[
[
1555,
24,
914
],
[
914,
24,
712
]
],
[
[
1555,
63,
886
],
[
886,
2... | [
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olsalazine"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfasalazine"
],
... | Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Sulfasalazine and Sulfasalazine (Compound) resembles Olsalazine (Compound)
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Diflunisal and Diflunisal may cause a moderate interaction th... |
DB00691 | DB01284 | 1,058 | 1,042 | [
"DDInter1237",
"DDInter1782"
] | Moexipril | Tetracosactide | Moexipril is a non-sulfhydryl containing precursor of the active angiotensin-converting enzyme (ACE) inhibitor moexiprilat. It is used to treat high blood pressure (hypertension). It works by relaxing blood vessels, causing them to widen. Lowering high blood pressure helps prevent strokes, heart attacks and kidney prob... | Tetracosactide (also known as Cosyntropin) is a synthetic peptide that is identical to the 24-amino acid segment (sequence: SYSMEHFRWGKPVGKKRRPVKVYP) at the N-terminal of adrenocorticotropic hormone. ACTH (1-24), a segment similar in all species, contains the biological activity that stimulates production of corticoste... | Moderate | 1 | [
[
[
1058,
24,
1042
]
],
[
[
1058,
24,
761
],
[
761,
63,
1042
]
],
[
[
1058,
24,
1144
],
[
1144,
24,
1042
]
],
[
[
1058,
40,
1638
],
[
1638... | [
[
[
"Moexipril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
]
],
[
[
"Moexipril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
],
[... | Moexipril may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin and Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide
Moexipril may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and N... |
DB00467 | DB09043 | 1,467 | 135 | [
"DDInter644",
"DDInter36"
] | Enoxacin | Albiglutide | A broad-spectrum 6-fluoronaphthyridinone antibacterial agent (fluoroquinolones) structurally related to nalidixic acid. | Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on A... | Moderate | 1 | [
[
[
1467,
24,
135
]
],
[
[
1467,
25,
126
],
[
126,
23,
135
]
],
[
[
1467,
63,
1647
],
[
1647,
23,
135
]
],
[
[
1467,
40,
739
],
[
739,
... | [
[
[
"Enoxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Albiglutide"
]
],
[
[
"Enoxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
],
[
"Warfarin",
... | Enoxacin may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Albiglutide
Enoxacin may cause a moderate interaction that could exacerbate diseases when taken with Acarbose and Acarbose may cause a minor inter... |
DB00535 | DB14491 | 1,145 | 428 | [
"DDInter315",
"DDInter725"
] | Cefdinir | Ferrous fumarate | Cefdinir, also known as Omnicef, is a semi-synthetic, broad-spectrum antibiotic belonging to the third generation of the cephalosporin class. It has been proven to be effective for the treatment of common bacterial infections in the ear, sinus, throat, lungs, and skin. Cefdinir was approved by the FDA in 1997 to treat ... | Used in treatment of iron deficiency anemia. | Moderate | 1 | [
[
[
1145,
24,
428
]
],
[
[
1145,
24,
1096
],
[
1096,
23,
428
]
],
[
[
1145,
24,
1384
],
[
1384,
24,
428
]
],
[
[
1145,
63,
597
],
[
597,
... | [
[
[
"Cefdinir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ferrous fumarate"
]
],
[
[
"Cefdinir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
],... | Cefdinir may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Ferrous fumarate
Cefdinir may cause a moderate interaction that could exacerbate diseases when taken with Magaldr... |
DB00563 | DB12615 | 663 | 1,381 | [
"DDInter1174",
"DDInter1482"
] | Methotrexate | Plazomicin | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | Developed by Achaogen biopharmaceuticals, plazomicin is a next-generation aminoglycoside synthetically derived from . The structure of plazomicin was established via appending hydroxylaminobutyric acid to at position 1 and 2-hydroxyethyl group at position 6' . It was designed to evade all clinically relevant aminoglyco... | Moderate | 1 | [
[
[
663,
24,
1381
]
],
[
[
663,
25,
1479
],
[
1479,
24,
1381
]
],
[
[
663,
64,
837
],
[
837,
24,
1381
]
],
[
[
663,
24,
416
],
[
416,
... | [
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Plazomicin"
]
],
[
[
"Methotrexate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acetylsalicylic acid"
],
[
... | Methotrexate may lead to a major life threatening interaction when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Plazomicin
Methotrexate may lead to a major life threatening interaction when taken with Pantoprazole and Pantoprazo... |
DB01097 | DB14444 | 1,377 | 151 | [
"DDInter1033",
"DDInter924"
] | Leflunomide | Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated) | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immuno... | Moderate | 1 | [
[
[
1377,
24,
151
]
],
[
[
1377,
64,
66
],
[
66,
24,
151
]
],
[
[
1377,
25,
1619
],
[
1619,
24,
151
]
],
[
[
1377,
25,
994
],
[
994,
... | [
[
[
"Leflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening intera... | Leflunomide may lead to a major life threatening interaction when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Leflunomide may lead to a major life threatening in... |
DB00635 | DB06414 | 1,573 | 655 | [
"DDInter1515",
"DDInter703"
] | Prednisone | Etravirine | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Etravirine is an antiretroviral agent more specifically classified as a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). Etraverine is used clinically for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. On January 18, 2007, the FDA granted accelerated approved for the use of etravirine 10... | Moderate | 1 | [
[
[
1573,
24,
655
]
],
[
[
1573,
6,
4973
],
[
4973,
45,
655
]
],
[
[
1573,
21,
28723
],
[
28723,
60,
655
]
],
[
[
1573,
63,
1101
],
[
1101... | [
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etravirine"
]
],
[
[
"Prednisone",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Prednisone (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Etravirine (Compound)
Prednisone (Compound) causes Malnutrition (Side Effect) and Malnutrition (Side Effect) is caused by Etravirine (Compound)
Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and ... |
DB00261 | DB01041 | 702 | 770 | [
"DDInter93",
"DDInter1789"
] | Anagrelide | Thalidomide | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythe... | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Moderate | 1 | [
[
[
702,
24,
770
]
],
[
[
702,
5,
11555
],
[
11555,
44,
770
]
],
[
[
702,
6,
7950
],
[
7950,
45,
770
]
],
[
[
702,
21,
29598
],
[
29598,
... | [
[
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Anagrelide",
"{u} (Compound) treats {v} (Disease)",
"hematologic cancer"
],
[
"hematologic cancer",
"{u} (Disea... | Anagrelide (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Thalidomide (Compound)
Anagrelide (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Thalidomide (Compound)
Anagrelide (Compound) causes Cellulitis (Side Effect) and Cellulitis (Side Effect) is caused by T... |
DB00365 | DB04845 | 839 | 309 | [
"DDInter842",
"DDInter1001"
] | Grepafloxacin | Ixabepilone | Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States. | Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. ... | Moderate | 1 | [
[
[
839,
24,
309
]
],
[
[
839,
23,
60
],
[
60,
23,
309
]
],
[
[
839,
24,
1419
],
[
1419,
24,
309
]
],
[
[
839,
25,
1619
],
[
1619,
6... | [
[
[
"Grepafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
]
],
[
[
"Grepafloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capecitabine"
],
... | Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Capecitabine and Capecitabine may cause a minor interaction that can limit clinical effects when taken with Ixabepilone
Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and I... |
DB01087 | DB12332 | 1,520 | 1,619 | [
"DDInter1520",
"DDInter1626"
] | Primaquine | Rucaparib | An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Ad... | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Moderate | 1 | [
[
[
1520,
24,
1619
]
],
[
[
1520,
62,
112
],
[
112,
23,
1619
]
],
[
[
1520,
63,
969
],
[
969,
24,
1619
]
],
[
[
1520,
24,
1662
],
[
1662,
... | [
[
[
"Primaquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Primaquine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Primaquine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Primaquine may cause a moderate interaction that could exacerbate diseases when taken with Ramelteon and Ramelt... |
DB00748 | DB00771 | 662 | 262 | [
"DDInter297",
"DDInter397"
] | Carbinoxamine | Clidinium | Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for carbinoxamine as an over the... | Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. It inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites. It is used for the tr... | Moderate | 1 | [
[
[
662,
24,
262
]
],
[
[
662,
24,
1511
],
[
1511,
63,
262
]
],
[
[
662,
24,
1688
],
[
1688,
1,
262
]
],
[
[
662,
63,
19
],
[
19,
24... | [
[
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clidinium"
]
],
[
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
],
... | Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Clidinium
Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Diphenoxylate ... |
DB05351 | DB06209 | 101 | 256 | [
"DDInter519",
"DDInter1508"
] | Dexlansoprazole | Prasugrel | Dexlansoprazole is a new-generation proton pump inhibitor (PPI) used for the management of symptoms associated with gastroesophageal reflux disease (GERD) and erosive esophagitis. Dexlansoprazole is the R-enantiomer of, which is composed of a racemic mixture of the R- and S-enantiomers. Compared to the older generation... | Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversib... | Minor | 0 | [
[
[
101,
23,
256
]
],
[
[
101,
62,
1479
],
[
1479,
24,
256
]
],
[
[
101,
23,
972
],
[
972,
63,
256
]
],
[
[
101,
25,
405
],
[
405,
6... | [
[
[
"Dexlansoprazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Prasugrel"
]
],
[
[
"Dexlansoprazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Acetylsalicylic acid"
... | Dexlansoprazole may cause a minor interaction that can limit clinical effects when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Prasugrel
Dexlansoprazole may cause a minor interaction that can limit clinical effects when taken w... |
DB01190 | DB01232 | 568 | 1,327 | [
"DDInter398",
"DDInter1640"
] | Clindamycin | Saquinavir | Clindamycin is a semi-synthetic lincosamide antibiotic used in the treatment of a variety of serious infections due to susceptible microorganisms[L11599,L11596] as well as topically for acne vulgaris. It has a relatively narrow spectrum of activity that includes anaerobic bacteria as well as gram-positive cocci and bac... | Saquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection. In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due... | Moderate | 1 | [
[
[
568,
24,
1327
]
],
[
[
568,
63,
798
],
[
798,
40,
1327
]
],
[
[
568,
6,
8374
],
[
8374,
45,
1327
]
],
[
[
568,
21,
28803
],
[
28803,
... | [
[
[
"Clindamycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saquinavir"
]
],
[
[
"Clindamycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nelfinavir"
],
[
... | Clindamycin may cause a moderate interaction that could exacerbate diseases when taken with Nelfinavir and Nelfinavir (Compound) resembles Saquinavir (Compound)
Clindamycin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Saquinavir (Compound)
Clindamycin (Compound) causes Anaemia (Side Effect) and Anaemia ... |
DB00459 | DB08903 | 640 | 996 | [
"DDInter21",
"DDInter170"
] | Acitretin | Bedaquiline | An oral retinoid effective in the treatment of psoriasis. It is the major metabolite of etretinate with the advantage of a much shorter half-life when compared with etretinate. | Bedaquiline is a bactericidal antimycobacterial drug belonging to the class of diarylquinoline. The quinolinic central heterocyclic nucleus with alcohol and amine side chains is responsible for bedaquiline-mediated antimycobacterial activity. Although it is closely related to fluoroquinolones, bedaquiline does not affe... | Moderate | 1 | [
[
[
640,
24,
996
]
],
[
[
640,
21,
29267
],
[
29267,
60,
996
]
],
[
[
640,
64,
964
],
[
964,
24,
996
]
],
[
[
640,
24,
1613
],
[
1613,
... | [
[
[
"Acitretin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bedaquiline"
]
],
[
[
"Acitretin",
"{u} (Compound) causes {v} (Side Effect)",
"Alanine aminotransferase increased"
],
[
"Alanine aminotransfe... | Acitretin (Compound) causes Alanine aminotransferase increased (Side Effect) and Alanine aminotransferase increased (Side Effect) is caused by Bedaquiline (Compound)
Acitretin may lead to a major life threatening interaction when taken with Doxycycline and Doxycycline may cause a moderate interaction that could exacerb... |
DB00349 | DB04868 | 902 | 478 | [
"DDInter401",
"DDInter1293"
] | Clobazam | Nilotinib | Clobazam belongs to the 1,5-benzodiazepine class of drugs and is marketed under different names, Onfi, Frisium, Urbanyl, and others.. Clobazam was first synthesized in 1966 and first published in 1969, following the incidental synthesis and discovery of the first benzodiazepine chlordiazepoxide in the 1950s. Unlike old... | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Moderate | 1 | [
[
[
902,
24,
478
]
],
[
[
902,
6,
4973
],
[
4973,
45,
478
]
],
[
[
902,
21,
28963
],
[
28963,
60,
478
]
],
[
[
902,
24,
1040
],
[
1040,
... | [
[
[
"Clobazam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Clobazam",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Clobazam (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Nilotinib (Compound)
Clobazam (Compound) causes Anxiety (Side Effect) and Anxiety (Side Effect) is caused by Nilotinib (Compound)
Clobazam may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may cau... |
DB00539 | DB11915 | 11 | 1,293 | [
"DDInter1837",
"DDInter1909"
] | Toremifene | Valbenazine | Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has est... | Valbenazine is a modified metabolite of [tetrabenazine], and it is currently being approved for the treatment of various movement disorders, particularly tardive dyskinesia and chorea associated with Huntington's disease.[L47885,A261135] Tardive dyskinesia has long been regarded as a consequence of anti-dopamine recept... | Major | 2 | [
[
[
11,
25,
1293
]
],
[
[
11,
23,
112
],
[
112,
23,
1293
]
],
[
[
11,
64,
521
],
[
521,
24,
1293
]
],
[
[
11,
25,
401
],
[
401,
24,
... | [
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Valbenazine"
]
],
[
[
"Toremifene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronid... | Toremifene may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Valbenazine
Toremifene may lead to a major life threatening interaction when taken with Goserelin and Goserelin may cause... |
DB08822 | DB13620 | 911 | 948 | [
"DDInter156",
"DDInter1499"
] | Azilsartan medoxomil | Potassium gluconate | Azilsartan medoxomil is a prodrug that is broken down to azilsartan, which belongs in the angiotensin-receptor blocking (ARB) drug class. It is a selective AT1 subtype angiotensin II receptor antagonist. Azilsartan medoxomil is a relatively recently-developed antihypertensive drug that was first approved by the FDA in ... | Potassium gluconate is a salt of and is classified as a food additive by the FDA . It is also used as a potassium supplement . Potassium is an essential nutrient. It is the most abundant cation in the intracellular fluid, where it plays a key role in maintaining cell function . In dietary supplements, potassium is ofte... | Major | 2 | [
[
[
911,
25,
948
]
],
[
[
911,
63,
176
],
[
176,
23,
948
]
],
[
[
911,
24,
1296
],
[
1296,
23,
948
]
],
[
[
911,
63,
848
],
[
848,
2... | [
[
[
"Azilsartan medoxomil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Potassium gluconate"
]
],
[
[
"Azilsartan medoxomil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glarg... | Azilsartan medoxomil may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a minor interaction that can limit clinical effects when taken with Potassium gluconate
Azilsartan medoxomil may cause a moderate interaction that could exacerbate disease... |
DB00635 | DB01377 | 1,573 | 1,283 | [
"DDInter1515",
"DDInter1119"
] | Prednisone | Magnesium oxide | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Magnesium oxide is an inorganic compound that occurs in nature as the mineral periclase. In aqueous media combines quickly with water to form magnesium hydroxide. It is used as an antacid and mild laxative and has many nonmedicinal uses. | Minor | 0 | [
[
[
1573,
23,
1283
]
],
[
[
1573,
24,
743
],
[
743,
23,
1283
]
],
[
[
1573,
63,
461
],
[
461,
23,
1283
]
],
[
[
1573,
24,
1482
],
[
1482,
... | [
[
[
"Prednisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium oxide"
]
],
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lisinopril"
],
[... | Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Lisinopril and Lisinopril may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide
Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Timolol and Timolo... |
DB00960 | DB09065 | 887 | 760 | [
"DDInter1471",
"DDInter424"
] | Pindolol | Cobicistat | Pindolol is a first generation non-selective beta blocker used in the treatment of hypertension. Early research into the use of pindolol found it had chronotropic effects, and so further investigation focused on the treatment of arrhythmia. Research into pindolol's use in the treatment of hypertension began in the earl... | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Moderate | 1 | [
[
[
887,
24,
760
]
],
[
[
887,
24,
1374
],
[
1374,
23,
760
]
],
[
[
887,
24,
868
],
[
868,
24,
760
]
],
[
[
887,
63,
870
],
[
870,
2... | [
[
[
"Pindolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
]
],
[
[
"Pindolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
],
[
... | Pindolol may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abiraterone may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Pindolol may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafen... |
DB00305 | DB11943 | 377 | 255 | [
"DDInter1232",
"DDInter495"
] | Mitomycin | Delafloxacin | Mitomycin is an antineoplastic antibiotic first isolated by Japanese microbiologists in the 1950s from cultures of _Streptomyces caespitosus_.[L12867,A193419] It is an alkylating agent that inhibits DNA synthesis (and, at higher concentrations, RNA and protein synthesis) by cross-linking the complementary strands of th... | Delafloxacin is a fluoroquinolone antibiotic which has been used in trials studying the treatment and basic science of Gonorrhea, Hepatic Impairment, Bacterial Skin Diseases, Skin Structure Infections, and Community Acquired Pneumonia, among others. It was approved in June 2017 under the trade name Baxdela for use in t... | Minor | 0 | [
[
[
377,
23,
255
]
],
[
[
377,
24,
1001
],
[
1001,
23,
255
]
],
[
[
377,
63,
552
],
[
552,
23,
255
]
],
[
[
377,
25,
970
],
[
970,
2... | [
[
[
"Mitomycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Delafloxacin"
]
],
[
[
"Mitomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mechlorethamine"
],
[... | Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Mechlorethamine and Mechlorethamine may cause a minor interaction that can limit clinical effects when taken with Delafloxacin
Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Carmustine an... |
DB00294 | DB00731 | 1,336 | 1,144 | [
"DDInter701",
"DDInter1269"
] | Etonogestrel | Nateglinide | Etonogestrel molecule is a 3-ketodesogestrel or 19-nortestosterone which is a synthetic biologically active metabolite of progestin desogestrel. The first product including etonogestrel was developed by the Merck subsidiary Organon and FDA approved in 2001. | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that ... | Moderate | 1 | [
[
[
1336,
24,
1144
]
],
[
[
1336,
6,
8374
],
[
8374,
45,
1144
]
],
[
[
1336,
21,
28787
],
[
28787,
60,
1144
]
],
[
[
1336,
24,
1051
],
[
1... | [
[
[
"Etonogestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
]
],
[
[
"Etonogestrel",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compou... | Etonogestrel (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Nateglinide (Compound)
Etonogestrel (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Nateglinide (Compound)
Etonogestrel may cause a moderate interaction that could exacerbate diseases when taken with Aminoglut... |
DB00009 | DB00081 | 1,271 | 273 | [
"DDInter56",
"DDInter1838"
] | Alteplase | Tositumomab | Alteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent. It cleaves plasminogen to form plasmin, an enzyme involved in the degradation of fibrin clots. In the absence of fibrin, the alteplase-mediated conversion of plasminogen is limited, thanks to the high affinity between alteplas... | Murine IgG2a lambda monoclonal antibody against CD20 antigen (2 heavy chains of 451 residues, 2 lambda chains of 220 residues). It is produced in an antibiotic-free culture of mammalian cells. It can be covalently linked to Iodine 131 (a radioactive isotope of iodine). | Major | 2 | [
[
[
1271,
25,
273
]
],
[
[
1271,
23,
539
],
[
539,
62,
273
]
],
[
[
1271,
24,
109
],
[
109,
63,
273
]
],
[
[
1271,
25,
1618
],
[
1618,
... | [
[
[
"Alteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tositumomab"
]
],
[
[
"Alteplase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
],
[
"Capsicum",
... | Alteplase may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may cause a minor interaction that can limit clinical effects when taken with Tositumomab
Alteplase may cause a moderate interaction that could exacerbate diseases when taken with Duloxetine and Duloxetine may ... |
DB00685 | DB00855 | 1,299 | 213 | [
"DDInter1887",
"DDInter72"
] | Trovafloxacin | Aminolevulinic acid | Trovafloxacin is a broad spectrum antibiotic that has been commonly marketed under the brand name Trovan by Pfizer. It exerts its antibacterial activity by inhibiting the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV. It was shown to be more effective again... | A compound produced from succinyl-CoA and glycine as an intermediate in heme synthesis. It is used as a photochemotherapy for actinic keratosis. [PubChem] | Major | 2 | [
[
[
1299,
25,
213
]
],
[
[
1299,
21,
28766
],
[
28766,
60,
213
]
],
[
[
1299,
24,
848
],
[
848,
64,
213
]
],
[
[
1299,
1,
956
],
[
956,
... | [
[
[
"Trovafloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aminolevulinic acid"
]
],
[
[
"Trovafloxacin",
"{u} (Compound) causes {v} (Side Effect)",
"Hypotension"
],
[
"Hypotension",
"{u} (Side Effect) is ... | Trovafloxacin (Compound) causes Hypotension (Side Effect) and Hypotension (Side Effect) is caused by Aminolevulinic acid (Compound)
Trovafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may lead to a major life threatening interaction when taken with Amino... |
DB00872 | DB01166 | 1,080 | 477 | [
"DDInter438",
"DDInter379"
] | Conivaptan | Cilostazol | Conivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2). | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | Major | 2 | [
[
[
1080,
25,
477
]
],
[
[
1080,
6,
8374
],
[
8374,
45,
477
]
],
[
[
1080,
21,
28658
],
[
28658,
60,
477
]
],
[
[
1080,
62,
126
],
[
126,
... | [
[
[
"Conivaptan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cilostazol"
]
],
[
[
"Conivaptan",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Cilosta... | Conivaptan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Cilostazol (Compound)
Conivaptan (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Cilostazol (Compound)
Conivaptan may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin m... |
DB08826 | DB14811 | 1,292 | 385 | [
"DDInter489",
"DDInter979"
] | Deferiprone | Isatuximab | Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. FDA ap... | Isatuximab (formerly SAR650984) is a humanized, IgG1-derived monoclonal antibody (mAb) produced from a Chinese hamster ovary (CHO) cell line.[L12099,A191799] Structurally, isatuximab is comprised of two identical immunoglobulin kappa light chains and two identical immunoglobulin gamma heavy chains. It is a cytolytic an... | Major | 2 | [
[
[
1292,
25,
385
]
],
[
[
1292,
25,
1362
],
[
1362,
24,
385
]
],
[
[
1292,
64,
377
],
[
377,
24,
385
]
],
[
[
1292,
64,
908
],
[
908,
... | [
[
[
"Deferiprone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Isatuximab"
]
],
[
[
"Deferiprone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olaparib"
],
[
"Olaparib",
"{u} may... | Deferiprone may lead to a major life threatening interaction when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Isatuximab
Deferiprone may lead to a major life threatening interaction when taken with Mitomycin and Mitomycin may cause a moderate interact... |
DB06282 | DB09118 | 516 | 1,580 | [
"DDInter1053",
"DDInter1711"
] | Levocetirizine | Stiripentol | Levocetirizine is a selective histamine H<sub>1</sub> antagonist used to treat a variety of allergic symptoms.[A181748,A181790,L7694] It is the R enantiomer of [cetirizine]. Levocetirizine has greater affinity for the histamine H<sub>1</sub> receptor than cetirizine. Levocetirizine was granted FDA approval in 1995. | Stiripentol is an antiepileptic agent that is an aromatic allylic alcohol drug, which makes it structurally unique from other antiepileptic drugs.[A19740, A250825] The clinical development and marketing of stiripentol were first delayed due to the drug's potent inhibitory effects on hepatic cytochrome P450 (CYP) enzyme... | Moderate | 1 | [
[
[
516,
24,
1580
]
],
[
[
516,
63,
1532
],
[
1532,
24,
1580
]
],
[
[
516,
24,
407
],
[
407,
63,
1580
]
],
[
[
516,
62,
1031
],
[
1031,
... | [
[
[
"Levocetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
],
[
[
"Levocetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
],... | Levocetirizine may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Levocetirizine may cause a moderate interaction that could exacerbate diseases when taken with Opium and Op... |
DB00242 | DB05015 | 1,064 | 1,077 | [
"DDInter392",
"DDInter174"
] | Cladribine | Belinostat | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | Belinostat is a novel agent that inhibits the enzyme histone deacetylase (HDAC) with a sulfonamide-hydroxamide structure. It was developed as an orphan drug to target hematological malignancies and solid tumors by TopoTarget. The safety and efficacy of belinostat is currently being evaluated for use in combination with... | Major | 2 | [
[
[
1064,
25,
1077
]
],
[
[
1064,
63,
1253
],
[
1253,
24,
1077
]
],
[
[
1064,
25,
482
],
[
482,
24,
1077
]
],
[
[
1064,
25,
1136
],
[
1136... | [
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Belinostat"
]
],
[
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palifermin"
],
[
"Palifermin... | Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Palifermin and Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Belinostat
Cladribine may lead to a major life threatening interaction when taken with Tioguanine and Tioguanine may cause ... |
DB01229 | DB11791 | 973 | 785 | [
"DDInter1377",
"DDInter287"
] | Paclitaxel | Capmatinib | Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intr... | Capmatinib is a small molecule kinase inhibitor targeted against c-Met (a.k.a. hepatocyte growth factor receptor [HGFR]), a receptor tyrosine kinase that, in healthy humans, activates signaling cascades involved in organ regeneration and tissue repair. Aberrant c-Met activation - via mutations, amplification, and/or ov... | Moderate | 1 | [
[
[
973,
24,
785
]
],
[
[
973,
63,
1324
],
[
1324,
24,
785
]
],
[
[
973,
24,
868
],
[
868,
24,
785
]
],
[
[
973,
24,
1320
],
[
1320,
... | [
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capmatinib"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
[
... | Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Capmatinib
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and V... |
DB01309 | DB04946 | 1,254 | 924 | [
"DDInter933",
"DDInter907"
] | Insulin glulisine | Iloperidone | Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas... | Iloperidone is an atypical antipsychotic for the treatment of schizophrenia symptoms. Hoechst Marion Roussel Inc. researched the drug until May 1996. In June 1997 they gave the research rights to Titan Pharmaceuticals, who gave the worldwide development, manufacturing, and marketing rights to Novartis in August 1998. O... | Moderate | 1 | [
[
[
1254,
24,
924
]
],
[
[
1254,
63,
1664
],
[
1664,
1,
924
]
],
[
[
1254,
63,
519
],
[
519,
40,
924
]
],
[
[
1254,
63,
170
],
[
170,
... | [
[
[
"Insulin glulisine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloperidone"
]
],
[
[
"Insulin glulisine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risperidone"... | Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Risperidone and Risperidone (Compound) resembles Iloperidone (Compound)
Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Paliperidone and Paliperidone (Compound) resembles I... |
DB00787 | DB01181 | 387 | 1,532 | [
"DDInter25",
"DDInter906"
] | Acyclovir | Ifosfamide | Acyclovir is a nucleotide analog antiviral used to treat herpes simplex, _Varicella zoster_, herpes zoster, herpes labialis, and acute herpetic keratitis[L7303,L7315,L7318,L7321,L7324,L7327]. Acyclovir is generally used first line in the treatment of these viruses and some products are indicated for patients as young a... | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Moderate | 1 | [
[
[
387,
24,
1532
]
],
[
[
387,
7,
5415
],
[
5415,
46,
1532
]
],
[
[
387,
21,
28956
],
[
28956,
60,
1532
]
],
[
[
387,
63,
1349
],
[
1349,... | [
[
[
"Acyclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Acyclovir",
"{u} (Compound) upregulates {v} (Gene)",
"UBQLN2"
],
[
"UBQLN2",
"{u} (Gene) is upregulated by {v} (C... | Acyclovir (Compound) upregulates UBQLN2 (Gene) and UBQLN2 (Gene) is upregulated by Ifosfamide (Compound)
Acyclovir (Compound) causes Palpitations (Side Effect) and Palpitations (Side Effect) is caused by Ifosfamide (Compound)
Acyclovir may cause a moderate interaction that could exacerbate diseases when taken with Mepe... |
DB00694 | DB01182 | 51 | 371 | [
"DDInter485",
"DDInter1534"
] | Daunorubicin | Propafenone | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated. | Moderate | 1 | [
[
[
51,
24,
371
]
],
[
[
51,
63,
847
],
[
847,
1,
371
]
],
[
[
51,
63,
675
],
[
675,
40,
371
]
],
[
[
51,
24,
455
],
[
455,
24,
... | [
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propafenone"
]
],
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atomoxetine"
],
... | Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Atomoxetine and Atomoxetine (Compound) resembles Propafenone (Compound)
Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Dextropropoxyphene and Dextropropoxyphene (Compound) resembles... |
DB00495 | DB00635 | 139 | 1,573 | [
"DDInter1961",
"DDInter1515"
] | Zidovudine | Prednisone | A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain... | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Moderate | 1 | [
[
[
139,
24,
1573
]
],
[
[
139,
24,
175
],
[
175,
40,
1573
]
],
[
[
139,
63,
251
],
[
251,
1,
1573
]
],
[
[
139,
24,
167
],
[
167,
1... | [
[
[
"Zidovudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisone"
]
],
[
[
"Zidovudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],
[... | Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Prednisone (Compound)
Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone (Compound) resembles Prednisone... |
DB00496 | DB11986 | 194 | 484 | [
"DDInter480",
"DDInter648"
] | Darifenacin | Entrectinib | Darifenacin (Enablex®, Novartis) is a medication used to treat urinary incontinence. Darifenacin blocks M3 muscarinic acetylcholine receptors, which mediate bladder muscle contractions. This block reduces the urgency to urinate and so it should not be used in people with urinary retention. It is unknown if M3 receptor ... | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Moderate | 1 | [
[
[
194,
24,
484
]
],
[
[
194,
24,
1320
],
[
1320,
24,
484
]
],
[
[
194,
24,
159
],
[
159,
63,
484
]
],
[
[
194,
63,
883
],
[
883,
2... | [
[
[
"Darifenacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Darifenacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
],
[
... | Darifenacin may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Darifenacin may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Laro... |
DB00072 | DB00445 | 550 | 322 | [
"DDInter1846",
"DDInter655"
] | Trastuzumab | Epirubicin | Produced in CHO cell cultures, trastuzumab is a recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein (HER2). It is used as a treatment of human epidermal growth ... | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Major | 2 | [
[
[
550,
25,
322
]
],
[
[
550,
24,
748
],
[
748,
63,
322
]
],
[
[
550,
63,
1257
],
[
1257,
24,
322
]
],
[
[
550,
24,
58
],
[
58,
24,... | [
[
[
"Trastuzumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Epirubicin"
]
],
[
[
"Trastuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
],
[
"Ant... | Trastuzumab may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine and Anthrax vaccine may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin
Trastuzumab may cause a moderate interaction that could exacerbate diseases when taken with Pegfilgra... |
DB00783 | DB01285 | 1,438 | 708 | [
"DDInter679",
"DDInter445"
] | Estradiol | Corticotropin | Estradiol is a naturally occurring hormone circulating endogenously in females. It is commercially available in several hormone therapy products for managing conditions associated with reduced estrogen, such as vulvovaginal atrophy and hot flashes. Some available forms of estradiol include oral tablets, injections, vag... | Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis. | Moderate | 1 | [
[
[
1438,
24,
708
]
],
[
[
1438,
23,
771
],
[
771,
62,
708
]
],
[
[
1438,
63,
245
],
[
245,
24,
708
]
],
[
[
1438,
24,
170
],
[
170,
... | [
[
[
"Estradiol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
]
],
[
[
"Estradiol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hyaluronidase"
],
[
... | Estradiol may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase and Hyaluronidase may cause a minor interaction that can limit clinical effects when taken with Corticotropin
Estradiol may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Gl... |
DB00814 | DB09134 | 1,171 | 1,552 | [
"DDInter1143",
"DDInter966"
] | Meloxicam | Ioversol | Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve various types of pain, including pain caused by musculoskeletal conditions, osteoarthritis, and rheumatoid arthritis. With a longer half-life than most other NSAIDS, it is a favorable option for those who require once-daily dosing. Meloxicam is ... | Ioversol is a non-ionic compound with a tri-iodinated benzene ring used as a contrast dye in diagnostic procedures to visualize different types of organs and tissues. Iodine has a high atomic density, which gives it the ability to attenuate X-rays. The intravascular administration of iodine compounds, such as ioversol,... | Major | 2 | [
[
[
1171,
25,
1552
]
],
[
[
1171,
24,
848
],
[
848,
25,
1552
]
],
[
[
1171,
63,
1274
],
[
1274,
25,
1552
]
],
[
[
1171,
1,
1027
],
[
1027,... | [
[
[
"Meloxicam",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ioversol"
]
],
[
[
"Meloxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
],
[
"Ibuprofen",
... | Meloxicam may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may lead to a major life threatening interaction when taken with Ioversol
Meloxicam may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may lead to ... |
DB00827 | DB01168 | 646 | 1,053 | [
"DDInter383",
"DDInter1526"
] | Cinoxacin | Procarbazine | Synthetic antimicrobial related to oxolinic acid and nalidixic acid and used in urinary tract infections. | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Minor | 0 | [
[
[
646,
23,
1053
]
],
[
[
646,
24,
848
],
[
848,
40,
1053
]
],
[
[
646,
21,
28762
],
[
28762,
60,
1053
]
],
[
[
646,
64,
126
],
[
126,
... | [
[
[
"Cinoxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Procarbazine"
]
],
[
[
"Cinoxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
],
[
... | Cinoxacin may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen (Compound) resembles Procarbazine (Compound)
Cinoxacin (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Procarbazine (Compound)
Cinoxacin may lead to a major life threatening... |
DB01041 | DB06176 | 770 | 1,342 | [
"DDInter1789",
"DDInter1616"
] | Thalidomide | Romidepsin | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Moderate | 1 | [
[
[
770,
24,
1342
]
],
[
[
770,
63,
112
],
[
112,
23,
1342
]
],
[
[
770,
24,
336
],
[
336,
24,
1342
]
],
[
[
770,
63,
485
],
[
485,
... | [
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
... | Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Romidepsin
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine and ... |
DB01021 | DB06655 | 674 | 5 | [
"DDInter1861",
"DDInter1077"
] | Trichlormethiazide | Liraglutide | A thiazide diuretic with properties similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p830) | Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist.[Label,A6932] Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmit... | Moderate | 1 | [
[
[
674,
24,
5
]
],
[
[
674,
63,
870
],
[
870,
24,
5
]
],
[
[
674,
40,
1326
],
[
1326,
24,
5
]
],
[
[
674,
24,
708
],
[
708,
24,
... | [
[
[
"Trichlormethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Trichlormethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocort... | Trichlormethiazide may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Trichlormethiazide (Compound) resembles Diclofenamide (Compound) and Diclofenamide may cause ... |
DB00208 | DB00348 | 1,018 | 254 | [
"DDInter1804",
"DDInter1300"
] | Ticlopidine | Nitisinone | Ticlopidine is an effective inhibitor of platelet aggregation. It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who ca... | Nitisinone is a synthetic reversible inhibitor of 4-hydroxyphenylpyruvate dioxygenase. It is used in the treatment of hereditary tyrosinemia type 1. It is sold under the brand name Orfadin. | Moderate | 1 | [
[
[
1018,
24,
254
]
],
[
[
1018,
21,
29276
],
[
29276,
60,
254
]
],
[
[
1018,
24,
1274
],
[
1274,
63,
254
]
],
[
[
1018,
23,
1220
],
[
122... | [
[
[
"Ticlopidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nitisinone"
]
],
[
[
"Ticlopidine",
"{u} (Compound) causes {v} (Side Effect)",
"Haemoglobin"
],
[
"Haemoglobin",
"{u} (Side Effect) i... | Ticlopidine (Compound) causes Haemoglobin (Side Effect) and Haemoglobin (Side Effect) is caused by Nitisinone (Compound)
Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken wi... |
DB04843 | DB09488 | 1,511 | 103 | [
"DDInter1149",
"DDInter23"
] | Mepenzolate | Acrivastine | Mepenzolate is a post-ganglionic parasympathetic inhibitor. It decreases gastric acid and pepsin secretion and suppresses spontaneous contractions of the colon. Mepenzolate diminishes gastric acid and pepsin secretion. Mepenzolate also suppresses spontaneous contractions of the colon. Pharmacologically, it is a post-ga... | Acrivastine is a triprolidine analog antihistamine indicated for the treatment of allergies and hay fever. As an H1 receptor antagonist, it functions by blocking the action of histamine at this receptor thereby preventing the symptoms associated with histamine release such as pruritis, vasodilation, hypotension, edema,... | Moderate | 1 | [
[
[
1511,
24,
103
]
],
[
[
1511,
63,
1405
],
[
1405,
24,
103
]
],
[
[
1511,
24,
573
],
[
573,
24,
103
]
],
[
[
1511,
74,
701
],
[
701,
... | [
[
[
"Mepenzolate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acrivastine"
]
],
[
[
"Mepenzolate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclobenzaprine"
],
... | Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Cyclobenzaprine and Cyclobenzaprine may cause a moderate interaction that could exacerbate diseases when taken with Acrivastine
Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Fesotero... |
DB00500 | DB00877 | 24 | 629 | [
"DDInter1831",
"DDInter1678"
] | Tolmetin | Sirolimus | A non-steroidal anti-inflammatory agent (anti-inflammatory agents, NON-steroidal) similar in mode of action to indomethacin. | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | Major | 2 | [
[
[
24,
25,
629
]
],
[
[
24,
7,
3727
],
[
3727,
46,
629
]
],
[
[
24,
21,
28898
],
[
28898,
60,
629
]
],
[
[
24,
24,
167
],
[
167,
24... | [
[
[
"Tolmetin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sirolimus"
]
],
[
[
"Tolmetin",
"{u} (Compound) upregulates {v} (Gene)",
"MAL"
],
[
"MAL",
"{u} (Gene) is upregulated by {v} (Compound)",
"Siroli... | Tolmetin (Compound) upregulates MAL (Gene) and MAL (Gene) is upregulated by Sirolimus (Compound)
Tolmetin (Compound) causes Constipation (Side Effect) and Constipation (Side Effect) is caused by Sirolimus (Compound)
Tolmetin may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone ... |
DB09075 | DB12035 | 498 | 943 | [
"DDInter621",
"DDInter1641"
] | Edoxaban | Sarecycline | Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to r... | Sarecycline is a semi-synthetic derivative of tetracycline that was initially discovered by Paratek Pharmaceuticals from Boston, MA but then licensed to Warner Chilcott of Rockaway, NJ in July of 2007 . After completing various phase-II and phase-III trials demonstrating its effectiveness in treating moderate to severe... | Major | 2 | [
[
[
498,
25,
943
]
],
[
[
498,
24,
1456
],
[
1456,
24,
943
]
],
[
[
498,
64,
1670
],
[
1670,
24,
943
]
],
[
[
498,
25,
1421
],
[
1421,
... | [
[
[
"Edoxaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sarecycline"
]
],
[
[
"Edoxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venetoclax"
],
[
"Venetoclax",
... | Edoxaban may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax and Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline
Edoxaban may lead to a major life threatening interaction when taken with Eliglustat and Eliglustat may cause a m... |
DB00777 | DB01309 | 146 | 1,254 | [
"DDInter1537",
"DDInter933"
] | Propiomazine | Insulin glulisine | Propiomazine, an atypical antipsychotic agent, is used to treat both negative and positive symptoms of schizophrenia, acute mania with bipolar disorder, agitation, and psychotic symptoms in dementia. Future uses may include the treatment of obsessive-compulsive disorder and severe behavioral disorders in autism. Struct... | Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas... | Moderate | 1 | [
[
[
146,
24,
1254
]
],
[
[
146,
64,
1621
],
[
1621,
23,
1254
]
],
[
[
146,
63,
274
],
[
274,
23,
1254
]
],
[
[
146,
63,
1645
],
[
1645,
... | [
[
[
"Propiomazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Propiomazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Potassium chloride"
],
... | Propiomazine may lead to a major life threatening interaction when taken with Potassium chloride and Potassium chloride may cause a minor interaction that can limit clinical effects when taken with Insulin glulisine
Propiomazine may cause a moderate interaction that could exacerbate diseases when taken with Phentolamin... |
DB00026 | DB00603 | 1,184 | 303 | [
"DDInter94",
"DDInter1137"
] | Anakinra | Medroxyprogesterone acetate | Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta.... | Medroxyprogesterone acetate (MPA) is a [progesterone] derivative that is more resistant to metabolism for improved pharmacokinetic properties. MPA can be use to treat secondary amenorrhea, endometrial hyperplasia, abnormal uterine bleeding, osteoporosis, vasomotor symptoms in menopause, vulvar and vaginal atrophy, prev... | Moderate | 1 | [
[
[
1184,
24,
303
]
],
[
[
1184,
24,
167
],
[
167,
1,
303
]
],
[
[
1184,
24,
700
],
[
700,
62,
303
]
],
[
[
1184,
63,
305
],
[
305,
... | [
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Medroxyprogesterone acetate"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone... | Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) resembles Medroxyprogesterone acetate (Compound)
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Atorvastatin and Atorvastatin may cause a minor ... |
DB01087 | DB01263 | 1,520 | 859 | [
"DDInter1520",
"DDInter1494"
] | Primaquine | Posaconazole | An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Ad... | Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients. | Moderate | 1 | [
[
[
1520,
24,
859
]
],
[
[
1520,
6,
8374
],
[
8374,
45,
859
]
],
[
[
1520,
21,
28757
],
[
28757,
60,
859
]
],
[
[
1520,
62,
112
],
[
112,
... | [
[
[
"Primaquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Posaconazole"
]
],
[
[
"Primaquine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)... | Primaquine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Posaconazole (Compound)
Primaquine (Compound) causes Dyspepsia (Side Effect) and Dyspepsia (Side Effect) is caused by Posaconazole (Compound)
Primaquine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and... |
DB06699 | DB09020 | 774 | 28 | [
"DDInter493",
"DDInter212"
] | Degarelix | Bisacodyl | Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH... | Bisacodyl, a diphenylmethane derivative, is a commonly used over the counter stimulant laxative for occasional constipation.[A233300,L13362] Both bisacodyl and [picosulfate] are metabolized to the same active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM).[A233290,A233300,A207700] Bisacodyl was patented on 2... | Moderate | 1 | [
[
[
774,
24,
28
]
],
[
[
774,
21,
28666
],
[
28666,
60,
28
]
],
[
[
774,
63,
739
],
[
739,
24,
28
]
],
[
[
774,
64,
540
],
[
540,
24... | [
[
[
"Degarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
]
],
[
[
"Degarelix",
"{u} (Compound) causes {v} (Side Effect)",
"Nervous system disorder"
],
[
"Nervous system disorder",
"... | Degarelix (Compound) causes Nervous system disorder (Side Effect) and Nervous system disorder (Side Effect) is caused by Bisacodyl (Compound)
Degarelix may cause a moderate interaction that could exacerbate diseases when taken with Lomefloxacin and Lomefloxacin may cause a moderate interaction that could exacerbate dis... |
DB00352 | DB10343 | 482 | 962 | [
"DDInter1814",
"DDInter160"
] | Tioguanine | Bacillus calmette-guerin substrain tice live antigen | An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. | Bacillus calmette-guerin substrain tice live antigen is a vaccine containing attenuated live culture preparation of the Bacillus of Calmette and Guerin (BCG) strain of *Mycobacterium bovis* for percutaneous use. It is administered to prevent the development of tuberculosis. | Major | 2 | [
[
[
482,
25,
962
]
],
[
[
482,
64,
1057
],
[
1057,
25,
962
]
],
[
[
482,
24,
270
],
[
270,
64,
962
]
],
[
[
482,
24,
663
],
[
663,
2... | [
[
[
"Tioguanine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bacillus calmette-guerin substrain tice live antigen"
]
],
[
[
"Tioguanine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
... | Tioguanine may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Bacillus calmette-guerin substrain tice live antigen
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizum... |
DB00741 | DB01377 | 167 | 1,283 | [
"DDInter885",
"DDInter1119"
] | Hydrocortisone | Magnesium oxide | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone wa... | Magnesium oxide is an inorganic compound that occurs in nature as the mineral periclase. In aqueous media combines quickly with water to form magnesium hydroxide. It is used as an antacid and mild laxative and has many nonmedicinal uses. | Minor | 0 | [
[
[
167,
23,
1283
]
],
[
[
167,
63,
743
],
[
743,
23,
1283
]
],
[
[
167,
24,
1482
],
[
1482,
62,
1283
]
],
[
[
167,
1,
1573
],
[
1573,
... | [
[
[
"Hydrocortisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium oxide"
]
],
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lisinopril"
... | Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Lisinopril and Lisinopril may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide
Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Digitoxin ... |
DB06643 | DB14004 | 1,136 | 398 | [
"DDInter500",
"DDInter1806"
] | Denosumab | Tildrakizumab | Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of osteoclasts. It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss.... | Tildrakizumab is a high-affinity, humanized, IgG1 κ antibody targeting interleukin 23 p19 that shows promise in the evolution of treatment strategy in chronic plaque psoriasis . The Food and Drug Administration (FDA) approved ILUMYA (tildrakizumab-asmn) for the treatment of adults with moderate-to-severe plaque psorias... | Moderate | 1 | [
[
[
1136,
24,
398
]
],
[
[
1136,
63,
58
],
[
58,
24,
398
]
],
[
[
1136,
24,
270
],
[
270,
24,
398
]
],
[
[
1136,
24,
375
],
[
375,
2... | [
[
[
"Denosumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tildrakizumab"
]
],
[
[
"Denosumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alefacept"
],
[
... | Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Tildrakizumab
Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocreli... |
DB00365 | DB09407 | 839 | 853 | [
"DDInter842",
"DDInter1114"
] | Grepafloxacin | Magnesium chloride | Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States. | Magnesium chloride salts are highly soluble in water and the hydrated form of magnesium chloride can be extracted from brine or sea water. | Moderate | 1 | [
[
[
839,
24,
853
]
],
[
[
839,
24,
544
],
[
544,
24,
853
]
],
[
[
839,
24,
460
],
[
460,
63,
853
]
],
[
[
839,
24,
544
],
[
544,
24,... | [
[
[
"Grepafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium chloride"
]
],
[
[
"Grepafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium sul... | Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium sulfate and Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Magnesium chloride
Grepafloxacin may cause a moderate interaction that could exacerbate diseases when take... |
DB09241 | DB14754 | 1,629 | 1,663 | [
"DDInter1186",
"DDInter1697"
] | Methylene blue | Solriamfetol | Methylene blue is an oxidation-reduction agent. The intravenous form of methylene blue is approved by the FDA for the treatment of pediatric and adult patients with acquired methemoglobinemia. Historically, it has been widely used in Africa to treat malaria, but now it disappeared when chloroquine (CQ) and other drugs ... | Solriamfetol marketed under the brand name Sunosi by Jazz Pharmaceuticals in the United States is a dopamine and norepinephrine reuptake inhibitor (DNRI) indicated in treating daytime sleepiness associated with narcolepsy or obstructive sleep apnea[FDA Label]. Solriamfetol was given FDA approval in 2019[FDA Label]. | Major | 2 | [
[
[
1629,
25,
1663
]
],
[
[
1629,
63,
1674
],
[
1674,
24,
1663
]
],
[
[
1629,
64,
1636
],
[
1636,
24,
1663
]
],
[
[
1629,
76,
1090
],
[
10... | [
[
[
"Methylene blue",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Solriamfetol"
]
],
[
[
"Methylene blue",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orciprenaline"
],
[
... | Methylene blue may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline and Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Solriamfetol
Methylene blue may lead to a major life threatening interaction when taken with Phenylephrine and Ph... |
DB06215 | DB06782 | 1,353 | 1,575 | [
"DDInter730",
"DDInter563"
] | Ferumoxytol | Dimercaprol | Ferumoxytol is an intravenously administered iron preparation indicated in the EU and the US for the treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD). It is comprised of superparamagnetic iron oxide nanoparticles which are coated by a semi-synthetic carbohydrate shell in an isoton... | Dimercaprol is a traditional chelating agent developed by British biochemists at Oxford University during World War II. It was developed as an experimental antidote against the arsenic-based poison gas Lewisite. It has been used clinically since 1949 in arsenic, cadmium and mercury poisoning. In addition, it has in the... | Major | 2 | [
[
[
1353,
25,
1575
]
],
[
[
1353,
63,
1596
],
[
1596,
25,
1575
]
],
[
[
1353,
24,
428
],
[
428,
64,
1575
]
],
[
[
1353,
63,
1596
],
[
1596... | [
[
[
"Ferumoxytol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dimercaprol"
]
],
[
[
"Ferumoxytol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iron"
],
[
"Iron",
... | Ferumoxytol may cause a moderate interaction that could exacerbate diseases when taken with Iron and Iron may lead to a major life threatening interaction when taken with Dimercaprol
Ferumoxytol may cause a moderate interaction that could exacerbate diseases when taken with Ferrous fumarate and Ferrous fumarate may lea... |
DB05812 | DB11901 | 1,374 | 913 | [
"DDInter8",
"DDInter107"
] | Abiraterone | Apalutamide | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Major | 2 | [
[
[
1374,
25,
913
]
],
[
[
1374,
62,
112
],
[
112,
23,
913
]
],
[
[
1374,
24,
110
],
[
110,
62,
913
]
],
[
[
1374,
63,
600
],
[
600,
... | [
[
[
"Abiraterone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
]
],
[
[
"Abiraterone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metron... | Abiraterone may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Polatuzumab vedo... |
DB06335 | DB08912 | 761 | 1,040 | [
"DDInter1646",
"DDInter462"
] | Saxagliptin | Dabrafenib | Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009. | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib... | Moderate | 1 | [
[
[
761,
24,
1040
]
],
[
[
761,
6,
16560
],
[
16560,
45,
1040
]
],
[
[
761,
21,
28900
],
[
28900,
60,
1040
]
],
[
[
761,
63,
168
],
[
168,... | [
[
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Saxagliptin",
"{u} (Compound) binds {v} (Gene)",
"SLC22A8"
],
[
"SLC22A8",
"{u} (Gene) is bound by {v} (Compoun... | Saxagliptin (Compound) binds SLC22A8 (Gene) and SLC22A8 (Gene) is bound by Dabrafenib (Compound)
Saxagliptin (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Dabrafenib (Compound)
Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Bort... |
DB06414 | DB09049 | 655 | 1,135 | [
"DDInter703",
"DDInter1261"
] | Etravirine | Naloxegol | Etravirine is an antiretroviral agent more specifically classified as a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). Etraverine is used clinically for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. On January 18, 2007, the FDA granted accelerated approved for the use of etravirine 10... | Naloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca. It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain. The advantage of naloxegol over the opioid antag... | Moderate | 1 | [
[
[
655,
24,
1135
]
],
[
[
655,
25,
1406
],
[
1406,
62,
1135
]
],
[
[
655,
24,
971
],
[
971,
62,
1135
]
],
[
[
655,
63,
1424
],
[
1424,
... | [
[
[
"Etravirine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
]
],
[
[
"Etravirine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neratinib"
],
[
"Neratinib",
... | Etravirine may lead to a major life threatening interaction when taken with Neratinib and Neratinib may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Etravirine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a... |
DB00501 | DB09381 | 752 | 192 | [
"DDInter380",
"DDInter678"
] | Cimetidine | Esterified estrogens | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant ... | Esterified estrogens contain a mixture of estrogenic substances; the principle component is estrone. Preparations contain 75% to 85% sodium estrone sulfate and 6% to 15% sodium equilin sulfate such that the total is not <90%. Esterified estrogens are a man-made mixture of estrogens that are used to treat symptoms of me... | Minor | 0 | [
[
[
752,
23,
192
]
],
[
[
752,
24,
1264
],
[
1264,
23,
192
]
],
[
[
752,
24,
723
],
[
723,
24,
192
]
],
[
[
752,
63,
1645
],
[
1645,
... | [
[
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Esterified estrogens"
]
],
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
... | Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a minor interaction that can limit clinical effects when taken with Esterified estrogens
Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Apre... |
DB00696 | DB09073 | 826 | 951 | [
"DDInter665",
"DDInter1379"
] | Ergotamine | Palbociclib | A vasoconstrictor found in ergot of Central Europe. It is an alpha-1 selective adrenergic agonist and is commonly used in the treatment of migraine disorders. | Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. Palbociclib was developed by Pfizer Inc after the discovery tha... | Moderate | 1 | [
[
[
826,
24,
951
]
],
[
[
826,
24,
1476
],
[
1476,
63,
951
]
],
[
[
826,
63,
600
],
[
600,
24,
951
]
],
[
[
826,
24,
578
],
[
578,
2... | [
[
[
"Ergotamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palbociclib"
]
],
[
[
"Ergotamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
[
... | Ergotamine may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib
Ergotamine may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluc... |
DB00018 | DB05679 | 199 | 1,683 | [
"DDInter945",
"DDInter1907"
] | Interferon alfa-n3 | Ustekinumab | Purified, natural (n is for natural) human interferon alpha proteins (consists of 3 forms or polymorphisms including 2a, 2b and 2c). 166 residues, some are glycosylated (MW range from 16 kD to 27 kD). | Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic dise... | Moderate | 1 | [
[
[
199,
24,
1683
]
],
[
[
199,
24,
126
],
[
126,
24,
1683
]
],
[
[
199,
25,
1648
],
[
1648,
24,
1683
]
],
[
[
199,
24,
270
],
[
270,
... | [
[
[
"Interferon alfa-n3",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
]
],
[
[
"Interferon alfa-n3",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
... | Interferon alfa-n3 may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Interferon alfa-n3 may lead to a major life threatening interaction when taken with Aldesleukin and Aldesle... |
DB00063 | DB09079 | 366 | 1,496 | [
"DDInter659",
"DDInter1296"
] | Eptifibatide | Nintedanib | Synthetic cyclic hexapeptide that binds to platelet receptor glycoprotein and inhibits platelet aggregation. Derived from venom of the Southeastern pygmy rattlesnake (Sistrurus miliarus barbouri), eptifibatide is a cyclic heptapeptide that belongs to the class of arginin-glycin-aspartat-mimetics. | Nintedanib is a small molecule kinase inhibitor used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and non-small cell lung cancer (NSCLC).[L8453,L8459] It was first approved for use in the United States in 2014. Within the spectrum of idiopathic pulmonary fibrosis trea... | Moderate | 1 | [
[
[
366,
24,
1496
]
],
[
[
366,
25,
707
],
[
707,
24,
1496
]
],
[
[
366,
64,
20
],
[
20,
24,
1496
]
],
[
[
366,
24,
477
],
[
477,
24... | [
[
[
"Eptifibatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nintedanib"
]
],
[
[
"Eptifibatide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Danaparoid"
],
[
"Danapa... | Eptifibatide may lead to a major life threatening interaction when taken with Danaparoid and Danaparoid may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib
Eptifibatide may lead to a major life threatening interaction when taken with Tenecteplase and Tenecteplase may cause a moder... |
DB09331 | DB11793 | 745 | 738 | [
"DDInter478",
"DDInter1297"
] | Daratumumab | Niraparib | Daratumumab is an immunoglobulin G1 kappa monoclonal antibody developed by Janssen and Genmab. It was first described in the literature in 2010 as a monoclonal antibody that targets CD38+ multiple myeloma cells; the first of its kind. Daratumumab was granted FDA approval on 16 November 2015. It is approved for the trea... | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | Moderate | 1 | [
[
[
745,
24,
738
]
],
[
[
745,
24,
496
],
[
496,
24,
738
]
],
[
[
745,
63,
440
],
[
440,
24,
738
]
],
[
[
745,
24,
1129
],
[
1129,
6... | [
[
[
"Daratumumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]
],
[
[
"Daratumumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]... | Daratumumab may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine and Hepatitis A Vaccine may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Daratumumab may cause a moderate interaction that could exacerbate diseases when taken with Fi... |
DB00912 | DB01083 | 473 | 1,142 | [
"DDInter1581",
"DDInter1348"
] | Repaglinide | Orlistat | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | The global prevalence of obesity is increasing rapidly. Obesity-related complications lead to significant personal and economic burden by reducing quality of life and increasing the cost of healthcare. In some individuals, diet and exercise are insufficient to maintain weight loss, and pharmacological or surgical inter... | Moderate | 1 | [
[
[
473,
24,
1142
]
],
[
[
473,
5,
11640
],
[
11640,
44,
1142
]
],
[
[
473,
6,
8374
],
[
8374,
45,
1142
]
],
[
[
473,
21,
28734
],
[
28734... | [
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orlistat"
]
],
[
[
"Repaglinide",
"{u} (Compound) treats {v} (Disease)",
"type 2 diabetes mellitus"
],
[
"type 2 diabetes mellitus",
... | Repaglinide (Compound) treats type 2 diabetes mellitus (Disease) and type 2 diabetes mellitus (Disease) is treated by Orlistat (Compound)
Repaglinide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Orlistat (Compound)
Repaglinide (Compound) causes Immune system disorder (Side Effect) and Immune system diso... |
DB00704 | DB06663 | 267 | 1,154 | [
"DDInter1263",
"DDInter1398"
] | Naltrexone | Pasireotide | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. | Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease. | Moderate | 1 | [
[
[
267,
24,
1154
]
],
[
[
267,
21,
28900
],
[
28900,
60,
1154
]
],
[
[
267,
24,
1247
],
[
1247,
23,
1154
]
],
[
[
267,
63,
663
],
[
663,
... | [
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pasireotide"
]
],
[
[
"Naltrexone",
"{u} (Compound) causes {v} (Side Effect)",
"Abdominal pain"
],
[
"Abdominal pain",
"{u} (Side Effe... | Naltrexone (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Pasireotide (Compound)
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects wh... |
DB01124 | DB01234 | 1,411 | 1,220 | [
"DDInter1828",
"DDInter513"
] | Tolbutamide | Dexamethasone | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release... | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Moderate | 1 | [
[
[
1411,
24,
1220
]
],
[
[
1411,
63,
870
],
[
870,
1,
1220
]
],
[
[
1411,
63,
175
],
[
175,
40,
1220
]
],
[
[
1411,
62,
1103
],
[
1103,
... | [
[
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
]
],
[
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
]... | Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Dexamethasone (Compound)
Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles D... |
DB00532 | DB01246 | 208 | 820 | [
"DDInter1152",
"DDInter45"
] | Mephenytoin | Alimemazine | Mephenytoin is used for the treatment of refractory partial epilepsy. Mephenytoin is a solid. This compound belongs to the phenylhydantoins. These are heterocyclic aromatic compounds containing an imiazolidinedione moiety substituted by a phenyl group. Mephenytoin is known to target sodium channel protein type 5 subuni... | A phenothiazine derivative that is used as an antipruritic. | Moderate | 1 | [
[
[
208,
24,
820
]
],
[
[
208,
24,
401
],
[
401,
24,
820
]
],
[
[
208,
24,
649
],
[
649,
1,
820
]
],
[
[
208,
63,
417
],
[
417,
23,
... | [
[
[
"Mephenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]
],
[
[
"Mephenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
... | Mephenytoin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine
Mephenytoin may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and... |
DB01098 | DB11718 | 14 | 927 | [
"DDInter1622",
"DDInter640"
] | Rosuvastatin | Encorafenib | Rosuvastatin, also known as the brand name product Crestor, is a lipid-lowering drug that belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage elevated lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin... | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Moderate | 1 | [
[
[
14,
24,
927
]
],
[
[
14,
63,
112
],
[
112,
23,
927
]
],
[
[
14,
63,
372
],
[
372,
24,
927
]
],
[
[
14,
24,
1491
],
[
1491,
24,
... | [
[
[
"Rosuvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Rosuvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
... | Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine ... |
DB00687 | DB13928 | 870 | 1,385 | [
"DDInter747",
"DDInter1660"
] | Fludrocortisone | Semaglutide | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to... | Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity.[A31421,L8681] Other members of this drug class include [Exenatide] and [Liraglutide]. Semaglutide was developed by Novo Nordisk and approved ... | Moderate | 1 | [
[
[
870,
24,
1385
]
],
[
[
870,
1,
1103
],
[
1103,
23,
1385
]
],
[
[
870,
64,
839
],
[
839,
24,
1385
]
],
[
[
870,
24,
359
],
[
359,
... | [
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
]
],
[
[
"Fludrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Amcinonide"
],
[
"Amcinonide",
"{u} may caus... | Fludrocortisone (Compound) resembles Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Semaglutide
Fludrocortisone may lead to a major life threatening interaction when taken with Grepafloxacin and Grepafloxacin may cause a moderate interaction that could... |
DB00459 | DB00618 | 640 | 1,572 | [
"DDInter21",
"DDInter498"
] | Acitretin | Demeclocycline | An oral retinoid effective in the treatment of psoriasis. It is the major metabolite of etretinate with the advantage of a much shorter half-life when compared with etretinate. | A tetracycline analog having a 7-chloro and a 6-methyl. Because it is excreted more slowly than tetracycline, it maintains effective blood levels for longer periods of time. | Major | 2 | [
[
[
640,
25,
1572
]
],
[
[
640,
25,
1620
],
[
1620,
1,
1572
]
],
[
[
640,
64,
964
],
[
964,
1,
1572
]
],
[
[
640,
25,
1669
],
[
1669,
... | [
[
[
"Acitretin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Demeclocycline"
]
],
[
[
"Acitretin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tetracycline"
],
[
"Tetracycline",
... | Acitretin may lead to a major life threatening interaction when taken with Tetracycline and Tetracycline (Compound) resembles Demeclocycline (Compound)
Acitretin may lead to a major life threatening interaction when taken with Doxycycline and Doxycycline (Compound) resembles Demeclocycline (Compound)
Acitretin may lead... |
DB00247 | DB05812 | 1,131 | 1,374 | [
"DDInter1194",
"DDInter8"
] | Methysergide | Abiraterone | An ergot derivative that is a congener of lysergic acid diethylamide. It antagonizes the effects of serotonin in blood vessels and gastrointestinal smooth muscle, but has few of the properties of other ergot alkaloids. Methysergide is used prophylactically in migraine and other vascular headaches and to antagonize sero... | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Moderate | 1 | [
[
[
1131,
24,
1374
]
],
[
[
1131,
21,
28809
],
[
28809,
60,
1374
]
],
[
[
1131,
25,
760
],
[
760,
62,
1374
]
],
[
[
1131,
24,
159
],
[
159... | [
[
[
"Methysergide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
]
],
[
[
"Methysergide",
"{u} (Compound) causes {v} (Side Effect)",
"Diarrhoea"
],
[
"Diarrhoea",
"{u} (Side Effect) is... | Methysergide (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Abiraterone (Compound)
Methysergide may lead to a major life threatening interaction when taken with Cobicistat and Cobicistat may cause a minor interaction that can limit clinical effects when taken with Abiraterone
Methyse... |
DB01041 | DB15091 | 770 | 676 | [
"DDInter1789",
"DDInter1901"
] | Thalidomide | Upadacitinib | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by syn... | Major | 2 | [
[
[
770,
25,
676
]
],
[
[
770,
24,
1430
],
[
1430,
24,
676
]
],
[
[
770,
63,
600
],
[
600,
24,
676
]
],
[
[
770,
63,
1184
],
[
1184,
... | [
[
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
],
[
"Sipu... | Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole a... |
DB08882 | DB09389 | 1,281 | 517 | [
"DDInter1070",
"DDInter1315"
] | Linagliptin | Norgestrel | Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes. Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin w... | Norgestrel is synthetic steroidal progestin that is used in combination with ethinyl estradiol for oral contraception. Norgestrel is composed of a racemic mixture of two stereoisomers, dextronorgestrel and levonorgestrel. However, only the levorotary enantiomer ([levonorgestrel]) is biologically active. | Moderate | 1 | [
[
[
1281,
24,
517
]
],
[
[
1281,
63,
1254
],
[
1254,
24,
517
]
],
[
[
1281,
24,
129
],
[
129,
24,
517
]
],
[
[
1281,
24,
1017
],
[
1017,
... | [
[
[
"Linagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norgestrel"
]
],
[
[
"Linagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
],... | Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine and Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Norgestrel
Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Enzal... |
DB01225 | DB09075 | 500 | 498 | [
"DDInter645",
"DDInter621"
] | Enoxaparin | Edoxaban | Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the inc... | Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to r... | Major | 2 | [
[
[
500,
25,
498
]
],
[
[
500,
23,
944
],
[
944,
62,
498
]
],
[
[
500,
24,
1004
],
[
1004,
63,
498
]
],
[
[
500,
24,
41
],
[
41,
24,... | [
[
[
"Enoxaparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Edoxaban"
]
],
[
[
"Enoxaparin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
],
[
"Chamomile",
... | Enoxaparin may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Edoxaban
Enoxaparin may cause a moderate interaction that could exacerbate diseases when taken with Phenyl salicylate and Phenyl ... |
DB00687 | DB00978 | 870 | 739 | [
"DDInter747",
"DDInter1084"
] | Fludrocortisone | Lomefloxacin | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to... | Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections (UTIs). Additionally, it has been employed for the prophylaxis of UTIs prior to surgery as well. | Major | 2 | [
[
[
870,
25,
739
]
],
[
[
870,
25,
945
],
[
945,
40,
739
]
],
[
[
870,
64,
1176
],
[
1176,
1,
739
]
],
[
[
870,
64,
1467
],
[
1467,
... | [
[
[
"Fludrocortisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomefloxacin"
]
],
[
[
"Fludrocortisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sparfloxacin"
],
[
"Sparfloxaci... | Fludrocortisone may lead to a major life threatening interaction when taken with Sparfloxacin and Sparfloxacin (Compound) resembles Lomefloxacin (Compound)
Fludrocortisone may lead to a major life threatening interaction when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Lomefloxacin (Compound)
Fludroco... |
DB00620 | DB09118 | 175 | 1,580 | [
"DDInter1855",
"DDInter1711"
] | Triamcinolone | Stiripentol | Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermat... | Stiripentol is an antiepileptic agent that is an aromatic allylic alcohol drug, which makes it structurally unique from other antiepileptic drugs.[A19740, A250825] The clinical development and marketing of stiripentol were first delayed due to the drug's potent inhibitory effects on hepatic cytochrome P450 (CYP) enzyme... | Moderate | 1 | [
[
[
175,
24,
1580
]
],
[
[
175,
24,
283
],
[
283,
63,
1580
]
],
[
[
175,
24,
473
],
[
473,
24,
1580
]
],
[
[
175,
62,
1018
],
[
1018,
... | [
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
],
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
... | Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide an... |
DB00365 | DB01229 | 839 | 973 | [
"DDInter842",
"DDInter1378"
] | Grepafloxacin | Paclitaxel (protein-bound) | Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States. | Paclitaxel can cause developmental toxicity, female reproductive toxicity and male reproductive toxicity according to state or federal government labeling requirements. | Moderate | 1 | [
[
[
839,
24,
973
]
],
[
[
839,
24,
310
],
[
310,
63,
973
]
],
[
[
839,
25,
1220
],
[
1220,
63,
973
]
],
[
[
839,
62,
134
],
[
134,
2... | [
[
[
"Grepafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Grepafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
... | Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Gr... |
DB00427 | DB00734 | 1,233 | 1,664 | [
"DDInter1879",
"DDInter1605"
] | Triprolidine | Risperidone | First generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness. | Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder. It is one of the most widely used SGAs. [Paliperidone], another commonly used SGA, is the primary active metabolite of risperidone (i.e. ... | Moderate | 1 | [
[
[
1233,
24,
1664
]
],
[
[
1233,
24,
924
],
[
924,
40,
1664
]
],
[
[
1233,
6,
12523
],
[
12523,
45,
1664
]
],
[
[
1233,
63,
1089
],
[
108... | [
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risperidone"
]
],
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloperidone"
],
... | Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Iloperidone and Iloperidone (Compound) resembles Risperidone (Compound)
Triprolidine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Risperidone (Compound)
Triprolidine may cause a moderate interaction that could e... |
DB08889 | DB09389 | 350 | 517 | [
"DDInter299",
"DDInter1315"
] | Carfilzomib | Norgestrel | Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combi... | Norgestrel is synthetic steroidal progestin that is used in combination with ethinyl estradiol for oral contraception. Norgestrel is composed of a racemic mixture of two stereoisomers, dextronorgestrel and levonorgestrel. However, only the levorotary enantiomer ([levonorgestrel]) is biologically active. | Major | 2 | [
[
[
350,
25,
517
]
],
[
[
350,
63,
14
],
[
14,
23,
517
]
],
[
[
350,
64,
581
],
[
581,
24,
517
]
],
[
[
350,
25,
375
],
[
375,
24,
... | [
[
[
"Carfilzomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Norgestrel"
]
],
[
[
"Carfilzomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rosuvastatin"
],
[
"Rosuva... | Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin and Rosuvastatin may cause a minor interaction that can limit clinical effects when taken with Norgestrel
Carfilzomib may lead to a major life threatening interaction when taken with Infliximab and Infliximab may ca... |
DB11093 | DB12035 | 636 | 943 | [
"DDInter273",
"DDInter1641"
] | Calcium citrate | Sarecycline | Calcium citrate is a salt typically used as a source of calcium in a variety of over the counter supplements. | Sarecycline is a semi-synthetic derivative of tetracycline that was initially discovered by Paratek Pharmaceuticals from Boston, MA but then licensed to Warner Chilcott of Rockaway, NJ in July of 2007 . After completing various phase-II and phase-III trials demonstrating its effectiveness in treating moderate to severe... | Moderate | 1 | [
[
[
636,
24,
943
]
],
[
[
636,
64,
115
],
[
115,
24,
943
]
],
[
[
636,
63,
819
],
[
819,
62,
417
],
[
417,
24,
943
]
],
[
[
636,
64,... | [
[
[
"Calcium citrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarecycline"
]
],
[
[
"Calcium citrate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aluminum hydroxide"
],
... | Calcium citrate may lead to a major life threatening interaction when taken with Aluminum hydroxide and Aluminum hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline
Calcium citrate may cause a moderate interaction that could exacerbate diseases when taken with Acebutolo... |
DB01261 | DB01364 | 170 | 22 | [
"DDInter1679",
"DDInter650"
] | Sitagliptin | Ephedrine | Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256]. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improv... | Ephedrine was first described in western literature in 1888, as a naturally occurring component of the ephedra plant, along with [pseudoephedrine]. Ephedrine acts as both a direct and indirect sympathomimetic. It is an alpha- and beta-adrenergic receptor agonist; however, it also causes the indirect release of norepine... | Moderate | 1 | [
[
[
170,
24,
22
]
],
[
[
170,
24,
1529
],
[
1529,
63,
22
]
],
[
[
170,
24,
280
],
[
280,
1,
22
]
],
[
[
170,
63,
1445
],
[
1445,
1,
... | [
[
[
"Sitagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ephedrine"
]
],
[
[
"Sitagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metamfetamine"
],
... | Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Metamfetamine and Metamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine
Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Mephentermine ... |
DB08816 | DB10672 | 578 | 297 | [
"DDInter1802",
"DDInter417"
] | Ticagrelor | Clove | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Clove allergenic extract is used in allergenic testing. | Minor | 0 | [
[
[
578,
23,
297
]
],
[
[
578,
24,
235
],
[
235,
62,
297
]
],
[
[
578,
64,
1564
],
[
1564,
23,
297
]
],
[
[
578,
63,
366
],
[
366,
2... | [
[
[
"Ticagrelor",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
]
],
[
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desirudin"
],
[
"Des... | Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Desirudin and Desirudin may cause a minor interaction that can limit clinical effects when taken with Clove
Ticagrelor may lead to a major life threatening interaction when taken with Defibrotide and Defibrotide may cause a minor... |
DB00845 | DB13074 | 1,490 | 877 | [
"DDInter406",
"DDInter1110"
] | Clofazimine | Macimorelin | Clofazimine is a highly lipophilic antimicrobial riminophenazine dye used in combination with other agents, such as [dapsone], for the treatment of leprosy. It was originally described in 1957 and was the prototypical riminophenazine dye - a bright-red dye that, in its clinical use, results in long-lasting discoloratio... | Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dep... | Major | 2 | [
[
[
1490,
25,
877
]
],
[
[
1490,
23,
112
],
[
112,
23,
877
]
],
[
[
1490,
24,
913
],
[
913,
24,
877
]
],
[
[
1490,
63,
543
],
[
543,
... | [
[
[
"Clofazimine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Clofazimine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metron... | Clofazimine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Macimorelin
Clofazimine may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and ... |
DB00834 | DB06595 | 932 | 1,491 | [
"DDInter1215",
"DDInter1214"
] | Mifepristone | Midostaurin | Mifepristone is a progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercor... | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Major | 2 | [
[
[
932,
25,
1491
]
],
[
[
932,
25,
1135
],
[
1135,
62,
1491
]
],
[
[
932,
23,
112
],
[
112,
23,
1491
]
],
[
[
932,
24,
761
],
[
761,
... | [
[
[
"Mifepristone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Midostaurin"
]
],
[
[
"Mifepristone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u... | Mifepristone may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Midostaurin
Mifepristone may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may c... |
DB08899 | DB09472 | 129 | 1,383 | [
"DDInter649",
"DDInter1693"
] | Enzalutamide | Sodium sulfate | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Sodium Sulfate Anhydrous is the anhydrous, sodium salt form of sulfuric acid. Sodium sulfate anhydrous disassociates in water to provide sodium ions and sulfate ions. Sodium ion is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Sodium sulfate... | Moderate | 1 | [
[
[
129,
24,
1383
]
],
[
[
129,
63,
1252
],
[
1252,
23,
1383
]
],
[
[
129,
63,
609
],
[
609,
24,
1383
]
],
[
[
129,
25,
1612
],
[
1612,
... | [
[
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digoxin"
],
... | Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Sodium sulfate
Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Cl... |
DB00059 | DB00586 | 1,560 | 1,512 | [
"DDInter1404",
"DDInter537"
] | Pegaspargase | Diclofenac | Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagi... | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first... | Moderate | 1 | [
[
[
1560,
24,
1512
]
],
[
[
1560,
24,
1263
],
[
1263,
63,
1512
]
],
[
[
1560,
24,
1622
],
[
1622,
24,
1512
]
],
[
[
1560,
25,
976
],
[
976... | [
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bromfenac"
],
[... | Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Bromfenac and Bromfenac may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Voriconazole and Vo... |
DB00188 | DB01175 | 168 | 318 | [
"DDInter222",
"DDInter672"
] | Bortezomib | Escitalopram | Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest ... | Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram]. It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible ... | Minor | 0 | [
[
[
168,
23,
318
]
],
[
[
168,
23,
1230
],
[
1230,
1,
318
]
],
[
[
168,
6,
8374
],
[
8374,
45,
318
]
],
[
[
168,
18,
3741
],
[
3741,
... | [
[
[
"Bortezomib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Escitalopram"
]
],
[
[
"Bortezomib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Citalopram"
],
[
... | Bortezomib may cause a minor interaction that can limit clinical effects when taken with Citalopram and Citalopram (Compound) resembles Escitalopram (Compound)
Bortezomib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Escitalopram (Compound)
Bortezomib (Compound) downregulates OXA1L (Gene) and OXA1L (Gene... |
DB00420 | DB00731 | 508 | 1,144 | [
"DDInter1532",
"DDInter1269"
] | Promazine | Nateglinide | A phenothiazine with actions similar to chlorpromazine but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. It is currently not approved for use in the United States. | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that ... | Moderate | 1 | [
[
[
508,
24,
1144
]
],
[
[
508,
6,
6017
],
[
6017,
45,
1144
]
],
[
[
508,
24,
609
],
[
609,
63,
1144
]
],
[
[
508,
24,
1424
],
[
1424,
... | [
[
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
]
],
[
[
"Promazine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
... | Promazine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Nateglinide (Compound)
Promazine may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide
Promazine ... |
DB00418 | DB00530 | 536 | 1,195 | [
"DDInter1650",
"DDInter667"
] | Secobarbital | Erlotinib | Secobarbital (marketed by Eli Lilly and Company under the brand names Seconal and Tuinal) is a barbiturate derivative drug with anaesthetic, anticonvulsant, sedative and hypnotic properties. It is commonly known as quinalbarbitone in the United Kingdom. | Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR)... | Moderate | 1 | [
[
[
536,
24,
1195
]
],
[
[
536,
63,
883
],
[
883,
40,
1195
]
],
[
[
536,
6,
7950
],
[
7950,
45,
1195
]
],
[
[
536,
21,
28762
],
[
28762,
... | [
[
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Erlotinib"
]
],
[
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gefitinib"
],
[
... | Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Gefitinib (Compound) resembles Erlotinib (Compound)
Secobarbital (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Erlotinib (Compound)
Secobarbital (Compound) causes Headache (Side Effect) and Headache... |
DB00574 | DB15035 | 121 | 503 | [
"DDInter717",
"DDInter1959"
] | Fenfluramine | Zanubrutinib | Dravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression. Concomitantly with these seizures, patients ty... | Zanubrutinib is a novel Bruton's tyrosine kinase (BTK) inhibitor used for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Mantle cell lymphoma is an aggressive mature B-cell non-Hodgkin lymphoma associated with early relapse, poor clinical outcomes, and long... | Moderate | 1 | [
[
[
121,
24,
503
]
],
[
[
121,
24,
868
],
[
868,
24,
503
]
],
[
[
121,
25,
222
],
[
222,
24,
503
]
],
[
[
121,
63,
1324
],
[
1324,
2... | [
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zanubrutinib"
]
],
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
],
... | Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Fenfluramine may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine ... |
DB06688 | DB15233 | 1,430 | 1,650 | [
"DDInter1677",
"DDInter142"
] | Sipuleucel-T | Avapritinib | Sipuleucel-T is a personalized, autologous, cellular immunotherapy. Sipuleucel-T is a therapeutic cancer vaccine for prostate cancer. Sipuleucel-T selectively targets the prostate-specific antigen (PSA) known as prostatic acid phosphatase (PAP) that is expressed in around 95% of prostate cancers. It must be prepared sp... | Avapritinib, or BLU-285, is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal stromal tumors and advanced systemic mastocytosis.[A189339,L40363] It is one of the first medications available for the trea... | Moderate | 1 | [
[
[
1430,
24,
1650
]
],
[
[
1430,
63,
1101
],
[
1101,
24,
1650
]
],
[
[
1430,
24,
270
],
[
270,
24,
1650
]
],
[
[
1430,
63,
908
],
[
908,
... | [
[
[
"Sipuleucel-T",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Avapritinib"
]
],
[
[
"Sipuleucel-T",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
... | Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib
Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and ... |
DB01115 | DB01211 | 336 | 609 | [
"DDInter1291",
"DDInter393"
] | Nifedipine | Clarithromycin | Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to [nicardipine].[A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972.[A175390,A190276] Since nifedipine's development,... | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Moderate | 1 | [
[
[
336,
24,
609
]
],
[
[
336,
6,
4973
],
[
4973,
45,
609
]
],
[
[
336,
7,
8733
],
[
8733,
57,
609
]
],
[
[
336,
18,
10375
],
[
10375,
... | [
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
]
],
[
[
"Nifedipine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)... | Nifedipine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Clarithromycin (Compound)
Nifedipine (Compound) upregulates PHGDH (Gene) and PHGDH (Gene) is downregulated by Clarithromycin (Compound)
Nifedipine (Compound) downregulates RPS4Y1 (Gene) and RPS4Y1 (Gene) is downregulated by Clarithromycin (Compound)
... |
DB00023 | DB00443 | 305 | 251 | [
"DDInter127",
"DDInter195"
] | Asparaginase Escherichia coli | Betamethasone | Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginas... | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | Moderate | 1 | [
[
[
305,
24,
251
]
],
[
[
305,
24,
617
],
[
617,
40,
251
]
],
[
[
305,
24,
167
],
[
167,
1,
251
]
],
[
[
305,
24,
1018
],
[
1018,
23... | [
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betamethasone"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with... | Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Budesonide and Budesonide (Compound) resembles Betamethasone (Compound)
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocort... |
DB00208 | DB00533 | 1,018 | 1,416 | [
"DDInter1804",
"DDInter1613"
] | Ticlopidine | Rofecoxib | Ticlopidine is an effective inhibitor of platelet aggregation. It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who ca... | Rofecoxib is used for the treatment of osteoarthritis, rheumatoid arthritis, acute pain in adults, and primary dysmenorrhea, as well as acute treatment of migraine attacks with or without auras. Rofecoxib is a solid. This compound belongs to the stilbenes. These are organic compounds containing a 1,2-diphenylethylene m... | Moderate | 1 | [
[
[
1018,
24,
1416
]
],
[
[
1018,
25,
1409
],
[
1409,
63,
1416
]
],
[
[
1018,
64,
1578
],
[
1578,
24,
1416
]
],
[
[
1018,
23,
167
],
[
167... | [
[
[
"Ticlopidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rofecoxib"
]
],
[
[
"Ticlopidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
],
[
"Apixaban",
... | Ticlopidine may lead to a major life threatening interaction when taken with Apixaban and Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Rofecoxib
Ticlopidine may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may cause a moderate interacti... |
DB00238 | DB12130 | 188 | 1,017 | [
"DDInter1285",
"DDInter1094"
] | Nevirapine | Lorlatinib | A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. Structurally, nevirapine belongs to the dipyridodiazepinone chemical class. | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Major | 2 | [
[
[
188,
25,
1017
]
],
[
[
188,
23,
608
],
[
608,
23,
1017
]
],
[
[
188,
24,
175
],
[
175,
24,
1017
]
],
[
[
188,
24,
971
],
[
971,
... | [
[
[
"Nevirapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lorlatinib"
]
],
[
[
"Nevirapine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",
... | Nevirapine may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcino... |
DB01577 | DB06603 | 1,529 | 39 | [
"DDInter1161",
"DDInter1387"
] | Metamfetamine | Panobinostat | Metamfetamine (methamphetamine) is a psychostimulant and sympathomimetic drug, and a member of the amphetamine group of sympathomimetic amines. Methamphetamine can induce effects such as euphoria, increased alertness and energy, and enhanced self-esteem. It is a scheduled drug in most countries due to its high potentia... | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Moderate | 1 | [
[
[
1529,
24,
39
]
],
[
[
1529,
63,
506
],
[
506,
24,
39
]
],
[
[
1529,
24,
144
],
[
144,
63,
39
]
],
[
[
1529,
1,
80
],
[
80,
24,
... | [
[
[
"Metamfetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Panobinostat"
]
],
[
[
"Metamfetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextromethorphan"
... | Metamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Metamfetamine may cause a moderate interaction that could exacerbate diseases when taken with O... |
DB00041 | DB00069 | 1,648 | 367 | [
"DDInter38",
"DDInter946"
] | Aldesleukin | Interferon alfacon-1 | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This... | Interferon alfacon-1 is a recombinant non-naturally occurring type-I interferon. The 166-amino acid sequence of Interferon alfacon-1 was derived by scanning the sequences of several natural interferon alpha subtypes and assigning the most frequently observed amino acid in each corresponding position. Four additional am... | Major | 2 | [
[
[
1648,
25,
367
]
],
[
[
1648,
24,
450
],
[
450,
62,
367
]
],
[
[
1648,
24,
599
],
[
599,
63,
367
]
],
[
[
1648,
63,
305
],
[
305,
... | [
[
[
"Aldesleukin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Interferon alfacon-1"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclophosphamide"
],
[... | Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Cyclophosphamide and Cyclophosphamide may cause a minor interaction that can limit clinical effects when taken with Interferon alfacon-1
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with... |
DB00855 | DB04951 | 213 | 187 | [
"DDInter72",
"DDInter1477"
] | Aminolevulinic acid | Pirfenidone | A compound produced from succinyl-CoA and glycine as an intermediate in heme synthesis. It is used as a photochemotherapy for actinic keratosis. [PubChem] | Pirfenidone is a synthetic pyridone drug. It is an antifibrotic agent with anti-inflammatory and antioxidant properties that is used to treat idiopathic pulmonary fibrosis (IPF), which is a chronic, progressive form of interstitial pneumonia. While its mechanism of action is not yet fully understood, pirfenidone is pro... | Major | 2 | [
[
[
213,
25,
187
]
],
[
[
213,
64,
92
],
[
92,
24,
187
]
],
[
[
213,
36,
842
],
[
842,
24,
187
]
],
[
[
213,
25,
33
],
[
33,
25,
... | [
[
[
"Aminolevulinic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pirfenidone"
]
],
[
[
"Aminolevulinic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methoxsalen"
],
[
"Metho... | Aminolevulinic acid may lead to a major life threatening interaction when taken with Methoxsalen and Methoxsalen may cause a moderate interaction that could exacerbate diseases when taken with Pirfenidone
Aminolevulinic acid (Compound) resembles Methyl aminolevulinate (Compound) and Aminolevulinic acid may lead to a ma... |
DB00834 | DB01156 | 932 | 593 | [
"DDInter1215",
"DDInter252"
] | Mifepristone | Bupropion | Mifepristone is a progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercor... | Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inh... | Moderate | 1 | [
[
[
932,
24,
593
]
],
[
[
932,
6,
8374
],
[
8374,
45,
593
]
],
[
[
932,
18,
10496
],
[
10496,
57,
593
]
],
[
[
932,
7,
8386
],
[
8386,
... | [
[
[
"Mifepristone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bupropion"
]
],
[
[
"Mifepristone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound... | Mifepristone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bupropion (Compound)
Mifepristone (Compound) downregulates ATP6V1D (Gene) and ATP6V1D (Gene) is downregulated by Bupropion (Compound)
Mifepristone (Compound) upregulates MTHFD2 (Gene) and MTHFD2 (Gene) is downregulated by Bupropion (Compound)
Mif... |
DB00286 | DB00451 | 380 | 542 | [
"DDInter440",
"DDInter1064"
] | Conjugated estrogens (topical) | Levothyroxine | Estrone sodium sulfate is a steroid sulfate and an organic sodium salt. It is functionally related to an estrone. | Levothyroxine is a synthetically produced form of thyroxine, a major endogenous hormone secreted by the thyroid gland. Also known as L-thyroxine or the brand name product Synthroid, levothyroxine is used primarily to treat hypothyroidism, a condition where the thyroid gland is no longer able to produce sufficient quant... | Moderate | 1 | [
[
[
380,
24,
542
]
],
[
[
380,
63,
1152
],
[
1152,
1,
542
]
],
[
[
380,
6,
15333
],
[
15333,
45,
542
]
],
[
[
380,
21,
28957
],
[
28957,
... | [
[
[
"Conjugated estrogens",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levothyroxine"
]
],
[
[
"Conjugated estrogens",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liot... | Conjugated estrogens may cause a moderate interaction that could exacerbate diseases when taken with Levothyroxine
Conjugated estrogens may cause a moderate interaction that could exacerbate diseases when taken with Liothyronine and Liothyronine (Compound) resembles Levothyroxine (Compound)
Conjugated estrogens (Compou... |
DB00748 | DB11632 | 662 | 580 | [
"DDInter297",
"DDInter1343"
] | Carbinoxamine | Opicapone | Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for carbinoxamine as an over the... | Opicapone is a potent, reversible, and peripherally-acting third-generation inhibitor of catechol-o-methyltransferase (COMT), an enzyme involved in the breakdown of various catecholamines including dopamine.[A36938, A203048] Many patients with Parkinson’s disease treated with levodopa plus a dopa decarboxylase (DDC) in... | Moderate | 1 | [
[
[
662,
24,
580
]
],
[
[
662,
24,
104
],
[
104,
24,
580
]
],
[
[
662,
35,
649
],
[
649,
24,
580
]
],
[
[
662,
63,
1219
],
[
1219,
2... | [
[
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opicapone"
]
],
[
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
... | Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Opicapone
Carbinoxamine (Compound) resembles Clofedanol (Compound) and Carbinoxamine may cause a moderate interactio... |
DB00056 | DB00827 | 816 | 646 | [
"DDInter814",
"DDInter383"
] | Gemtuzumab ozogamicin | Cinoxacin | Gemtuzumab ozogamicin is a recombinant humanized IgG4 kappa antibody which is conjugated with calicheamicin derivative, a cytotoxic antitumor antibiotic isolated from fermentation of Micromonospora echinospora ssp. calichensis. Gemtuzumab ozogamicin has approximately 50% of the antibody loaded with 4-6 moles calicheami... | Synthetic antimicrobial related to oxolinic acid and nalidixic acid and used in urinary tract infections. | Minor | 0 | [
[
[
816,
23,
646
]
],
[
[
816,
24,
322
],
[
322,
23,
646
]
],
[
[
816,
24,
869
],
[
869,
62,
646
]
],
[
[
816,
24,
663
],
[
663,
24,... | [
[
[
"Gemtuzumab ozogamicin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cinoxacin"
]
],
[
[
"Gemtuzumab ozogamicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubic... | Gemtuzumab ozogamicin may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a minor interaction that can limit clinical effects when taken with Cinoxacin
Gemtuzumab ozogamicin may cause a moderate interaction that could exacerbate diseases when taken with To... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.